Gossamer Bio, Inc. (GOSS) News
Track canonical SquawkNews coverage tagged to GOSS, Gossamer Bio, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Gossamer Bio announces up to $250 million private placement
Gossamer Bio says it has entered a structured private placement for up to $250 million, including $150 million of committed capital, to fund seralutinib through potential FDA approval.
MNA | Aug 21, 2026, 12:01 PM UTC
M
Gossamer Bio announces up to $250M private placement for seralutinib
Gossamer Bio says it has entered a structured private placement for up to $250M, including $150M of committed capital, to fund seralutinib through potential FDA approval and operations into 2028.
MNA | Aug 21, 2026, 12:00 PM UTC
L
GOSS upgraded from Market Perform to Outperform W/ $1 PT @ Leerink
GOSS upgraded from Market Perform to Outperform W/ $1 PT @ Leerink
EQUITY | Jul 28, 2026, 11:24 AM UTC
L
GOSS u/g Outperform @ Leerink pt 100
GOSS u/g Outperform @ Leerink pt 100
EQUITY | Jul 28, 2026, 09:15 AM UTC
L
Top Small Cap Positive News Movers Premarket: LGHL: +120% Momentum Mover MTNB: +62% Sales Agreement Terminated DFNS: +59% SC 13D Filed BIYA
Top Small Cap Positive News Movers Premarket: LGHL: +120% Momentum Mover MTNB: +62% Sales Agreement Terminated DFNS: +59% SC 13D Filed BIYA: +44% Momentum Mover VTAK: +29% Partners with 319 Golf Society and Named Exclusi
EQUITY | Jul 27, 2026, 12:16 PM UTC